Back to search

University of Patras

Επιπολασμός γονιδιακών μεταλλάξεων σε ασθενείς με θηλώδες καρκίνωμα του θυρεοειδούς και έκβαση της νόσου σε ελληνικό πληθυσμό

Abstract

dc:description

The incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma (PTC) ranges between 38-91% (mean 45% ) and correlates with aggressive behavior. There are no data for the Greek population. Our goal is to detect the BRAF V600E mutation and the possible synergistic role with TERTC228T / C250T mutations as prognostic indicators in Greek patients with PTC. This retrospective study includes 85 patients with PTC, with total or almost total thyroidectomy, ± lymph node cleaning who received 50-100mCi of 131I. Thyroglobulin levels (basal and stimulated), anti-thyroglobulin antibodies, and findings from whole-body scans and cervical ultrasound, 1, 3, 5 and 10 years after initial treatment were recorded. Patients were categorized as: the likelihood of recurrence of the disease (low, medium and high), the response to the initial treatment (excellent / incomplete residual disease and indeterminate) and disease course according to ATA 2015 guidelines for differentiated thyroid cancer. DNA was isolated from the histological preparations and tested for the presence of the BRAF V600E mutation and in 32 patients for t TERT C228T / C250T mutation. The initial classification of the risk of disease recurrence was performed without taking into account the presence or absence of mutations of the genes under invesigation.The BRAF V600E mutation was detected in 40 out of 82 patients (48.78%), the TERT gene mutation in 4 out of 32 patients (12.5%), which also carried the BRAF V600E.Reccurence was observed in 5 patients all of them were genotyped as BRAF positive (100%) whereas only one BRAF V600E (1/4 patients, 25%) had remote metastases.Four patients were positive for BRAF V600E and TERT C228T mutations. Two were of high risk for relapse, one of which was lost to follow-up, 2 remained with residual local disease up to 5 years of follow-up. The third was at risk and had a local relapse at 3 years of follow-up, while the 4th was low-risk with an excellent response to treatment without relapse.In conclusion, BRAF V600E mutation is detected in the Greek population in a frequency in accordance with the international literature, and its presence may be a poor prognostic factor, however administration of 131 I in all patients as well as the relatively small sample size do not allow for safe conclusions to be drawn. The aggravating role of BRAF V600E / TERT coexistence is a probability.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Agalianou, Niki
  • Αγαλιανού, Νίκη

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45825

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Agalianou, Niki; Αγαλιανού, Νίκη. Επιπολασμός γονιδιακών μεταλλάξεων σε ασθενείς με θηλώδες καρκίνωμα του θυρεοειδούς και έκβαση της νόσου σε ελληνικό πληθυσμό. University of Patras, 2019. http://hdl.handle.net/10442/hedi/45825